MetaVia (MTVA, Financial) has announced encouraging outcomes from the multiple ascending dose (MAD) phase of its Phase 1 clinical trial for DA-1726, a dual oxyntomodulin analog agonist. The trial examined its efficacy as a potential obesity treatment, targeting both glucagon-like peptide-1 (GLP-1) and glucagon receptors.
The 28-day study included 36 participants and demonstrated a clear, dose-responsive reduction in body weight across doses ranging from 8 mg to 32 mg. Higher doses and prolonged usage appeared to enhance efficacy, offering promising prospects for weight loss interventions. Additionally, body mass index (BMI) showed distinct improvements compared to the placebo group, emphasizing the drug's dose-dependent effectiveness on weight-related metrics.
Importantly, DA-1726 did not result in any clinically significant heart rate increases or QTcF changes at doses up to 32 mg over the four-week period. The drug's distinctive 3:1 GLP-1 and glucagon receptor activation could provide a viable alternative to current GLP-1 agonists, which are known for significant tolerability issues, contributing to high dropout rates early in treatment.
Looking ahead, MetaVia plans to initiate a Phase 1 Part 3 study. This phase will focus on DA-1726’s effectiveness and safety in patients who prematurely discontinued another obesity treatment, Wegovy. These efforts aim to highlight DA-1726’s superior tolerability, safety, and weight loss potential.
Throughout the trial, DA-1726 demonstrated favorable safety and tolerability profiles, with no treatment-related discontinuations or serious adverse events reported. Notably, 83% of subjects receiving the highest dose experienced early satiety, suggesting that extending treatment could yield even greater weight loss results.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for MetaVia Inc (MTVA, Financial) is $26.67 with a high estimate of $48.00 and a low estimate of $10.00. The average target implies an upside of 3,540.00% from the current price of $0.73. More detailed estimate data can be found on the MetaVia Inc (MTVA) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, MetaVia Inc's (MTVA, Financial) average brokerage recommendation is currently 1.5, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
